ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2025 When to…
